CMS announces new ICD-10 codes for COVID-19 monoclonal antibodies
In addition to the seven new 2022 ICD-10 procedure codes announced in November, the Centers for Medicare & Medicaid Services on April 1 will implement two new ICD-10 procedure codes for reporting COVID-19 therapeutics. The new codes are for describing the infusion of tixagevimab and cilgavimab monoclonal antibody (code XW023X7), and the infusion of other new technology monoclonal antibody (code XW023Y7).
The Food and Drug Administration last month authorized using the combination monoclonal antibody therapy Evusheld (tixagevimab co-packaged with cilgavimab) to help prevent COVID-19 in certain adults and children with compromised immune systems or a history of severe adverse reaction to a COVID-19 vaccine or its components.
Related News Articles
Headline
The Centers for Disease Control and Prevention last night endorsed Moderna’s COVID-19 vaccine for children aged 6-17, as its advisory committee…
Headline
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices today unanimously recommended Moderna’s COVID-19 vaccine for…
Headline
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices on Saturday recommended the Moderna vaccine for children aged 6…
Headline
The Food and Drug Administration today authorized Moderna’s COVID-19 vaccine for children aged 6 months through 17 years old and Pfizer’s COVID-19 vaccine for…
Headline
A Food and Drug Administration advisory committee today recommended the agency authorize Moderna’s COVID-19 two-dose vaccine for children aged 6 months…
Headline
An initial 10 million doses of COVID-19 vaccine are available for children under age 5 if the Food and Drug Administration authorizes and the Centers for…